Abatacept (powder), CAS 332348-12-6

Product Description: Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases[1][2][3].

Formula: N/A

References: [1]Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22./[2]Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12./[3]Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38.

CAS Number: 332348-12-6

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer; Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: CTLA-4

• Artikelnummer: MEXHY-108829A-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-108829A-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK